Evidence map›Paper›PMID 42787258›Full record

ReviewFrontiers in cell and developmental biology2026

ZAK kinase at the crossroads of cellular stress: functional plasticity, human pathobiology, and precision therapeutics.

Yeteng Xiong, Fei Luo, Yuhan Huang, Bingnan Li, Guanchuan Lin

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yeteng XiongThe First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Fei LuoSchool of Public Health, Southern Medical University, Guangzhou, China.
Yuhan HuangThe First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Bingnan LiSchool of Public Health, Southern Medical University, Guangzhou, China.
Guanchuan LinDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, and Guangdong Provincial Key Laboratory of Single Cell and Extracellular Vesicles, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitogen-activated protein kinase kinase 20 (MAP3K20/ZAK) has emerged as a critical biophysical sensor, uniquely poised at the intersection of environmental stress and cellular fate. Its versatile signaling is primarily orchestrated by two structurally distinct splice variants: ZAKα, which drives the ribotoxic stress response (RSR) upon detecting ribosome collisions, and ZAKβ, which mediates homeostatic mechanotransduction. However, emerging evidence indicates that the biological roles of ZAK cannot be strictly categorized as either pathogenic or protective. It exhibits profound functional plasticity and engages non-canonical metabolic networks in a highly context-dependent manner. Consequently, dysregulated ZAK signaling acts as a powerful disease amplifier across diverse human pathologies, including aggressive malignancies, cardiac remodeling, systemic metabolic deterioration, and inherited myopathies. While targeting ZAK presents a compelling therapeutic opportunity, current broad-spectrum kinase inhibitors are heavily confounded by "on-target, off-tissue" toxicities, particularly within the epidermal barrier. In this review, we synthesize the structural mechanisms, downstream cascades, and complex pathobiology of ZAK. Furthermore, we discuss an emerging Frontier in ZAK pharmacology: the conceptual development of structure-guided, isoform-selective allosteric interventions designed to safely decouple pathogenic ZAKα signaling from essential ZAKβ-mediated tissue homeostasis.

Indexed as

cellular pathologyisoform specificityprecision therapyribotoxic stress responsesignalingZAK kinase

Identifiers

PMID42787258
PMCPMC13601347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.